See more : National Electronics Holdings Limited (0213.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Kraig Biocraft Laboratories, Inc. (KBLB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kraig Biocraft Laboratories, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- APL Apollo Tubes Limited (APLAPOLLO.NS) Income Statement Analysis – Financial Results
- Bradda Head Lithium Limited (BHLIF) Income Statement Analysis – Financial Results
- Shuttle Inc. (2405.TW) Income Statement Analysis – Financial Results
- Belon Joint Stock Company (BLNG.ME) Income Statement Analysis – Financial Results
- New Vista Acquisition Corp (NVSAW) Income Statement Analysis – Financial Results
Kraig Biocraft Laboratories, Inc. (KBLB)
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. engages in developing protein-based fibers using recombinant DNA technology for commercial applications in the technical textile and specialty fiber industries in the United States. The company's products are used in military and police applications for ballistic protection; industrial applications, including critical cables and abrasion/impact resistant components; safety equipment; and composite materials for the aero-space industry. Its products are also used in various markets, such as medical textiles, geotextiles, defense and military textiles, safe and protective clothing, filtration textiles, composites with textile structure, and functional and sportive textiles, as well as textiles used in buildings and transportation. The company was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 401.62K | 97.32K | 31.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 27.62K | 28.10K | 3.68B | 13.09B | 14.79B | 11.52B | 10.56B | 16.97K | 15.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.62K | -28.10K | -3.68B | -13.09B | -14.79B | -11.52B | -10.56B | 14.88K | -15.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,868,283.05% | -10,850,924.48% | 46.72% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 237.87K | 176.43K | 197.75K | 88.47K | 223.05K | 148.07K | 258.89K | 397.14K | 432.01K | 439.54K | 489.43K | 465.29K | 250.60K | 141.31K | 69.80K | 33.08K | 177.02K | 164.91K |
| General & Administrative | 1.58M | 1.94M | 2.56M | 4.45M | 2.40M | 1.21M | 1.99M | 2.58M | 1.62M | 1.39M | 1.79M | 695.11K | 1.05M | 1.05M | 427.51K | 320.00K | 300.00K | 370.00K |
| Selling & Marketing | 797.41K | 0.00 | 0.00 | 0.00 | 0.00 | -2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.01K | -13.34K | -5.25K |
| SG&A | 2.38M | 1.94M | 2.56M | 4.45M | 2.40M | 1.21M | 1.99M | 2.58M | 1.62M | 1.39M | 1.79M | 695.11K | 1.05M | 1.05M | 427.51K | 312.99K | 286.66K | 364.75K |
| Other Expenses | 0.00 | 779.74B | 734.43B | 516.33B | 627.20B | -1.00 | 2.00 | -4.00 | -2.00 | -4.00 | -5.19M | 3.00K | 598.00 | 93.91K | 27.20K | 12.65K | 6.21K | -5.09K |
| Operating Expenses | 2.61M | 2.12M | 2.76M | 4.53M | 2.62M | 1.36M | 2.25M | 2.98M | 2.05M | 1.83M | 2.28M | 1.16M | 1.30M | 1.29M | 524.71K | 355.65K | 472.86K | 529.67K |
| Cost & Expenses | 2.61M | 2.12M | 2.76M | 4.53M | 2.62M | 1.36M | 2.25M | 2.98M | 2.05M | 1.83M | 2.28M | 1.16M | 1.30M | 1.29M | 524.71K | 355.65K | 472.86K | 529.67K |
| Interest Income | 0.00 | 1.72K | 5.36K | 386.62 | 6.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.00 | 192.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 375.10K | 609.13K | 660.42K | 386.62K | 294.35K | 228.95K | 177.11K | 139.43K | 101.55K | 69.28K | 0.00 | 45.71K | 0.00 | 52.38K | 41.81K | 7.24K | 122.00 | 654.00 |
| Depreciation & Amortization | 27.62K | 28.10K | 26.14K | 28.07K | 30.78K | 26.63K | 20.29K | 16.97K | 15.42K | 7.16K | 5.89K | 5.58K | 5.37K | 453.00 | 27.40K | -2.78K | 0.00 | 0.00 |
| EBITDA | -2.59M | -2.09M | -2.73M | -4.56M | -2.58M | -913.39K | -2.14M | -2.92M | -2.04M | -1.83M | -2.22M | -1.55M | -1.29M | -1.64M | -2.72M | -355.65K | -472.86K | -529.67K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -232.39% | -2,194.56% | -9,192.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.61M | -2.12M | -2.76M | -4.53M | -2.62M | -959.95K | -2.16M | -2.95M | -2.05M | -1.83M | -2.28M | -1.16M | -1.30M | -1.29M | -524.71K | -355.65K | -472.86K | -529.67K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -239.02% | -2,215.41% | -9,246.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -414.99K | -1.72M | -5.29M | -437.13K | -287.98K | -209.03K | -177.11K | -128.24K | -79.25K | -38.63K | -5.25M | -1.60M | 2.10K | -589.06K | -907.38K | -4.46K | -122.00 | -333.00 |
| Income Before Tax | -3.03M | -3.84M | -8.05M | -4.97M | -2.91M | -1.17M | -2.33M | -3.07M | -2.13M | -1.87M | -7.47M | -1.20M | -1.30M | -1.78M | -2.79M | -360.10K | -472.99K | -530.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -291.07% | -2,397.40% | -9,648.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.72M | 660.42K | 386.62K | 294.35K | 19.92K | 0.00 | 139.43K | 101.55K | 69.28K | 0.00 | 48.71K | 0.00 | 52.38K | 41.81K | 7.24K | 0.00 | 321.00 |
| Net Income | -3.03M | -5.56M | -8.71M | -5.36M | -3.20M | -1.17M | -2.33M | -3.07M | -2.13M | -1.87M | -7.47M | -1.20M | -1.30M | -1.78M | -2.79M | -360.10K | -472.99K | -530.32K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -291.07% | -2,397.40% | -9,648.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.03B | 974.31M | 877.61M | 848.65M | 835.59M | 816.87M | 791.39M | 744.28M | 685.84M | 662.49M | 616.31M | 596.14M | 572.71M | 401.59M | 504.12M | 499.73M | 411.63M | 329.50M |
| Weighted Avg Shares Out (Dil) | 1.03B | 974.31M | 877.61M | 848.65M | 835.59M | 816.87M | 791.39M | 744.28M | 685.84M | 662.49M | 616.31M | 596.14M | 572.71M | 401.59M | 504.12M | 499.73M | 411.63M | 329.50M |
Kraig Biocraft Laboratories Announces BAM-1 Spider Silk Hybrids are in Production
ANN ARBOR, Mich., June 03, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that Kraig Labs is now in production with its BAM-1 recombinant spider silk hybrids.
Kraig Biocraft Laboratories Shares Update on Dragon Silk Production Utilizing the BAM-1 Platform
Ann Arbor, Michigan--(Newsfile Corp. - May 28, 2024) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs") announces an update on the commercialization of its BAM-1 recombinant spider silk production hybrids. First made public in February of...
Kraig Biocraft Laboratories Prepares to Accelerate Production Launch following Spring Trials Success
Ann Arbor, Michigan--(Newsfile Corp. - May 20, 2024) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has completed its analysis of its spring spider silk production trials. Kraig Labs is rapidly integrating...
Kraig Biocraft Laboratories Provides a Statement on the Market Response to Recent Company Milestones and Shareholder Communications
Ann Arbor, Michigan--(Newsfile Corp. - May 15, 2024) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company"), announces that it remains proud to share information relating to its recent progress and the resounding success of the spring production trials. The Company...
Kraig Biocraft Laboratories Announces Intention to Diversify and Expand its Production Base
Ann Arbor, Michigan--(Newsfile Corp. - May 13, 2024) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it is pursuing a possible business expansion into Cambodia to support the rapid growth and diversification of...
24/7 Market News Publishes Report on Recent Spider Silk Production Breakthroughs Featuring Kraig Biocraft Laboratories
Denver, Colorado--(Newsfile Corp. - May 10, 2024) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report on Kraig Biocraft Laboratories' (OTCQB: KBLB) successful completion of its...
Kraig Biocraft Laboratories Spring Spider Silk Production Trials Exceed Expectations
Kraig Labs (OTCQB:KBLB) BAM-1 spider silk spring production trials exceed expectations and Implementing Next Phase of Its Recombinant Spider Silk Plan
Kraig Biocraft Laboratories Spring Production Trials Exceed Expectations for the Production of the Company's Recombinant Spider Silk
Ann Arbor, Michigan--(Newsfile Corp. - May 6, 2024) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that the spring production trials of the Company's new BAM-1 hybrid parental strains have concluded, exceeding all expectations...
Kraig Biocraft Laboratories Reports Signing Landmark Agreements in South East Asia
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company"), announces today that it has signed key agreements with the Lam Dong Agro-Forestry Research Experiment Center ("LAREC"), the sericulture authority in central Vietnam,...
Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials
Kraig Labs (OTCQB: KBLB) achieves major milestone; completes new BAM-1 1st gen parental strain rearing and cocoons at rates that exceeded expectations
Source: https://incomestatements.info
Category: Stock Reports